Step Therapy for Medicare Part B Drugs Will Mean New Responsibilities for P&T Committee New Rules for Part D and C Plans Mean Modest Changes for Drug Accessibility

摘要

The Trump administration's decision last May to ditch its plan to force insurance companies and pharmacy benefit managers (PBMs) to pass through manufacturer rebates to seniors was a major story and grabbed a lot of headlines. That reversal-after the White House and Health and Human Services (HHS) Secretary Alex Azar had publicly backed passing through rebates to consumers-meant that a number of important changes in Medicare drug policies that will go into effect next year didn't the get the attention they deserve.